These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 32259446)

  • 1. Molecule Property Analyses of Active Compounds for
    Makarov V; Salina E; Reynolds RC; Kyaw Zin PP; Ekins S
    J Med Chem; 2020 Sep; 63(17):8917-8955. PubMed ID: 32259446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.
    Stover CK; Warrener P; VanDevanter DR; Sherman DR; Arain TM; Langhorne MH; Anderson SW; Towell JA; Yuan Y; McMurray DN; Kreiswirth BN; Barry CE; Baker WR
    Nature; 2000 Jun; 405(6789):962-6. PubMed ID: 10879539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent Progress in the Discovery and Development of 2-Nitroimidazooxazines and 6-Nitroimidazooxazoles to Treat Tuberculosis and Neglected Tropical Diseases.
    Showalter HD
    Molecules; 2020 Sep; 25(18):. PubMed ID: 32927749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
    Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C
    Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of heterocyclic replacements for the coumarin core of anti-tubercular FadD32 inhibitors.
    Fang C; Lee KK; Nietupski R; Bates RH; Fernandez-Menendez R; Lopez-Roman EM; Guijarro-Lopez L; Yin Y; Peng Z; Gomez JE; Fisher S; Barros-Aguirre D; Hubbard BK; Serrano-Wu MH; Hung DT
    Bioorg Med Chem Lett; 2018 Dec; 28(22):3529-3533. PubMed ID: 30316633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in the research of heterocyclic compounds as antitubercular agents.
    Yan M; Ma S
    ChemMedChem; 2012 Dec; 7(12):2063-75. PubMed ID: 23042656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New potential drug leads against MDR-MTB: A short review.
    Gatadi S; Nanduri S
    Bioorg Chem; 2020 Jan; 95():103534. PubMed ID: 31884135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Players in Tuberculosis Drug Development: Another Break in the Cell Wall.
    Squeglia F; Romano M; Ruggiero A; Berisio R
    Curr Med Chem; 2017 Nov; 24(36):3954-3969. PubMed ID: 28183257
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Sawicki R; Ginalska G
    Future Med Chem; 2019 Aug; 11(16):2193-2203. PubMed ID: 31538522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening.
    Manjunatha UH; Smith PW
    Bioorg Med Chem; 2015 Aug; 23(16):5087-97. PubMed ID: 25577708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug design and identification of potent leads against mycobacterium tuberculosis thymidine monophosphate kinase.
    Van Calenbergh S; Pochet S; Munier-Lehmann H
    Curr Top Med Chem; 2012; 12(7):694-705. PubMed ID: 22283813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current Advances in Antitubercular Drug Discovery: Potent Prototypes and New Targets.
    Dos Santos Fernandes GF; Jornada DH; de Souza PC; Chin CM; Pavan FR; Dos Santos JL
    Curr Med Chem; 2015; 22(27):3133-61. PubMed ID: 26282941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elaboration of a proprietary thymidylate kinase inhibitor motif towards anti-tuberculosis agents.
    Song L; Risseeuw MDP; Froeyen M; Karalic I; Goeman J; Cappoen D; Van der Eycken J; Cos P; Munier-Lehmann H; Van Calenbergh S
    Bioorg Med Chem; 2016 Nov; 24(21):5172-5182. PubMed ID: 27614917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining cheminformatics methods and pathway analysis to identify molecules with whole-cell activity against Mycobacterium tuberculosis.
    Sarker M; Talcott C; Madrid P; Chopra S; Bunin BA; Lamichhane G; Freundlich JS; Ekins S
    Pharm Res; 2012 Aug; 29(8):2115-27. PubMed ID: 22477069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microbiology. An antibiotic mimics immunity.
    Nathan C
    Science; 2008 Nov; 322(5906):1337-8. PubMed ID: 19039126
    [No Abstract]   [Full Text] [Related]  

  • 17. Synthesis and structure activity relationships of cyanopyridone based anti-tuberculosis agents.
    Jian Y; Hulpia F; Risseeuw MDP; Forbes HE; Munier-Lehmann H; Caljon G; Boshoff HIM; Van Calenbergh S
    Eur J Med Chem; 2020 Sep; 201():112450. PubMed ID: 32623208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-throughput screen identifies small molecule inhibitors targeting acetyltransferase activity of Mycobacterium tuberculosis GlmU.
    Rani C; Mehra R; Sharma R; Chib R; Wazir P; Nargotra A; Khan IA
    Tuberculosis (Edinb); 2015 Dec; 95(6):664-677. PubMed ID: 26318557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maximizing bactericidal activity with combinations of bioreduced drugs.
    Goldman RC
    Future Med Chem; 2010 Aug; 2(8):1253-71. PubMed ID: 21426017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-Arylaminouracil Derivatives: New Inhibitors of Mycobacterium tuberculosis.
    Matyugina E; Novikov M; Babkov D; Ozerov A; Chernousova L; Andreevskaya S; Smirnova T; Karpenko I; Chizhov A; Murthu P; Lutz S; Kochetkov S; Seley-Radtke KL; Khandazhinskaya AL
    Chem Biol Drug Des; 2015 Dec; 86(6):1387-96. PubMed ID: 26061192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.